More than a pen...
Changing the way we diagnose and monitor neuromotor impairments
A unique and patented concept that combines movement related sensor technologies, integrated into a digital pen with an analytical engine and decision support system. Patients perform standardised handwriting and drawing tasks with the unique pen on a tablet computer, which non-invasively records parameters of minute limb and hand motions
What matters most to us
Expertise
Changing the way we diagnose and monitor neuromotor impairments to improve patients' well being and greater convenience for clinicians.
Technology
Our patented technology and unique diagnostic algorithms record validated biomarkers of neuromotor impairments to differentiate between movements and radically improve patient diagnosis and disease management.
Privacy
We follow strict data management protocols and have a robust, secure data-processing architecture within our cloud-based facility that has been provided by SmartPoints™.
Respect
We respect our patients' autonomy and privacy.
Meet the team
Board of Directors
Rutger is founding CEO of Manus Neurodynamica Ltd – the company that created the NeuroMotor Pen (NMP). The NMP is a medical device which objectively and accurately assesses for neuromotor impairments. While working with a small consulting firm, Rutger developed ideas to utilise neuroscience from his earlier PhD research to create novel, easily implementable clinical tools. Manus was founded as a channel to realise those ideas. Rutger coordinated the EU project, DiPAR, which facilitated initial product development and clinical validation. Prior to his PhD, Rutger gained experience in biomedical engineering (J&J Cordis Europe, Philips DAP and Medical systems) and project management for the Dutch healthcare sector (Cap Gemini). He also has post-graduate degrees in Bioengineering and Business administration.
Keith supports Manus Neurodynamica and has been in the life sciences industry for over 30 years, having graduated from Heriot Watt University in Marine Biology and gaining a PhD from the University College of North Wales. Since then, Keith has worked in pharmaceutical development at Covance, Global Head of Life Sciences at PA Consulting Group and Head of Life Sciences Equity Research at Lazard & Co. Keith was Head of Life Sciences Research at Wood Mackenzie for two years before establishing his own consultancy business for life science companies. He joined finnCap in October 2007 with a mandate to build its Life Science franchise and by November 2015, it was the largest in the sector on the Alternative Investment Market. Keith retired from his role in finnCap in April 2016.
Guy Wood-Gush
Non-Executive Director
Having graduated in medicine from Kings College in London, Guy practiced in Opthalmology and neurosurgery before moving to a career in business. This has included roles in operations as well as finance. His experience includes drug development at Eli Lilly and working in Healthcare investment banking first as a stock analyst with Barclays de Zoete Wedd and then in mergers and acquisitions with JPMorgan. Investment banking highlights include the demerger of ICI and IPO of Zeneca (now AstraZeneca) and the Wellcome £2.3bn stock offering (the largest in UK corporate history at the time). He subsequently became Chief Executive of Cancer Research Ventures, the technology transfer company for the Cancer Research Campaign. Since then he has been Chairman of Cambridge Cognition Ltd and Chief Executive of Deontics Ltd. which he cofounded and spun out from the University of Oxford. He has been a Trustee of the Royal Society of Medicine and holds an MBA from INSEAD.
Albert Nicholl
Chairman
Albert has extensive commercial experience in healthcare having worked at a senior level in companies such as Stryker and Orthofix. In recent years he has worked in a variety of non-exec roles supporting growing companies in the sector to raise investment, build great teams and commercialise successfully.
Advisory Board Members
PD Dr Angela Deutschlander, MD
Neurogeneticist and Movement Disorder specialist Consultant, who practised in Germany and US. Author and co-author of over 70 peer-reviewed manuscripts and book chapters. Angela has Neurology Consultant Associations with Mayo Clinic Florida, USA and the University of Munich, Germany.
Professor John Harrison
Expert psychologist with a special interest in cognition. John is Principal Consultant at Metis Cognition, a psychology practice established to advise with the selection and successful integration of cognitive testing into therapeutic development programs. He is also an Associate Professor with the AUmc Alzheimer Center and Visiting Professor at King’s College London. He holds Chartered Psychologist status and has authored/co-authored more than 80 books and scientific articles, including a popular neuroscience book ‘Synaesthesia: The Strangest Thing’.
Dr Terry O’Brien
Extensive experience as a senior executive and consultant within the Healthcare Industry. Co-founder and CEO of LiDCO Group PLC. Last 7 years providing medical technology consultancy advice for start-up to early commercial-stage medical technology companies with regards to commercial and go-to-market strategy. Education - Ph.D. in Stem Cell Transplantation from Westminster Medical School (now Imperial College, London), Bachelors in Human Biology from Surrey University.
Prof Richard Walker
Consultant Physician, Honorary Professor of Ageing and International Health, specialist in Parkinson’s and healthcare of the elderly at Northumbria NHS Foundation Trust, Clinical lead for Northumbria PD Service and director of R&D for the Trust. Closely involved both locally and nationally with the DeDRoN Research Network. Main research interest are Parkinson’s disease (UK) and also stroke in Sub-Saharan Africa (SSA) and Tanzania.
Prof Michael Caligiuri, University of California San Diego
Prof Caligiuri’s research focuses on understanding how motor function and impairment can be useful in the diagnosis and treatment of neurological and psychiatric illnesses. The clinical focus is on movement disorders with particular emphasis on differentiating idiopathic or degenerative disorders from medication-induced disorders and developing technologies for the rapid quantification of extrapyramidal motor signs such as tremor, dyskinesia and bradykinesia.
Significant research contributions include: the demonstration that early drug-induced parkinsonism can predict long-term persistent movement disorders in patients treated with antipsychotics; that antipsychotics and or mood stabilizers normalize cortical and subcortical hyperactivity in patients with bipolar disorder.
Prof Michele Hu
Michele Hu is a Professor at the Nuffield Department of Clinical Neurosciences, University of Oxford and Honorary Consultant Neurologist at Oxford University Hospitals. Michele is co-Principle Investigator with Professor Richard Wade-Martins of the Oxford Parkinson’s Disease Centre, and leads the Clinical Theme of this £10.7 million Monument Discovery 10 year award funded by Parkinson’s UK to understand the earliest pathological pathways in PD. Her research within the Oxford Parkinson's Disease Centre (www.opdc.ox.ac.uk) looks at longitudinal cohort studies and biomarkers for early and prodromal Parkinson's disease, with particular focus on REM sleep behavior disorder (RBD) and how sleep affects neurodegeneration. Her interests include the delivery of tractable, low-cost, wearable technology that has a real impact on people's daily lives and imaging the human brain, from prodromal to established Parkinson's.
The Team
Roberto Marcucci
VP of Sales
Roberto serves as the VP of Sales for Manus Neurodynamica and he brings an experience of almost 20 years in international sales leadership for medical devices and SaaS.
Strong in managing complex distribution channel structures operating in multicultural environments, Roberto likes to consider new approaches while solving daily challenges and is constantly on the hunt for something new to learn. Passionate for innovative Health-Tech solutions with a special interest in Neurology/Neurosurgery. Roberto holds a Bachelor of Engineering from Oxford Brookes University and has worked at senior levels at Natus Medical and Omniscient Neurotechnology.
Phil Pattison
CFO
Phil is a finance and commercial professional, who has held positions as director or senior manager for numerous blue-chip companies including; General Electric, Rolls-Royce, Marks and Spencer, Newcastle Science City and Royal IHC. In 2005 he and other fellow directors set up a specialist skincare company and floated on AIM.
Phil is a Fellow of the Institute of Management Accountants, a Chartered Banker and holds an MBA from Newcastle University. Whilst at GE he was Compliance Leader and a Black Belt in Six Sigma, business process improvement. His projects generated an additional $1m in profit and $3m in cash in six months.
Chris Papasavvas
Senior Data Scientist
Christoforos serves as the Senior Data Scientist of Manus Neurodynamica Ltd. He supports the mission of the company by applying his skills towards further research and development of the NeuroMotor Pen, thus maximizing its potential in clinical practice. He studied informatics at the University of Patras and the University of Edinburgh before embarking on neuroscientific research at Newcastle. He received his PhD from Newcastle University in 2017 and he gained post-doctoral research experience at Newcastle, Sussex and Yale. His research portfolio spans topics from basic neuroscience to computational neurology, with his work being published in highly reputed scientific journals. His expertise in signal processing and statistical modeling provides solutions for intelligent data analysis and efficient extraction of the clinically-useful information from the data collected through our device. He works closely with the Chief Systems Architect of the team to ensure rapid deployment of the analytics algorithms so that they are readily available to our collaborators in the clinics.
Dr David Bramwell
CTO
David’s goal as COO is for the technology to realise its huge potential in positively impacting millions of lives. He focuses on driving a process of continual improvement across all aspects of product delivery by building on the Quality Management Systems and the solid foundation of ISO 13485:2016.
David graduated in Microelectronics and Software Engineering where a collaborative project sparked his interest in neural systems. He then studied for his PhD researching human perception of colours. Postdoctoral research in the human neural dynamics of combined sensory stimuli followed, before David joined Nonlinear Dynamics Ltd. where he led development culminating in the release of the flagship Progenesis product line. Nonlinear developed an AI solution promising a step change in hypothesis free proteomics. Biosignatures spun that IP out, with David as CEO, and the goal to use the new technology to discover novel blood biomarker panels for urological cancers.
Karen de Lange
Assistant Management Accountant
Sanja Bojic
Clinical Specialist
Karen is Manus Neurodynamica’s Assistant Management Accountant. Before joining Manus, she fulfilled finance roles within the retail, manufacturing and SaaS sectors.
Sanja is a medical doctor with a Ph.D. in Regenerative Medicine. She works on clinical collaborations and provides support to clinical and academic users. Before joining the Manus Neurodynamica team, she has worked at Newcastle University for 7 seven years. Her medical expertise enables an understanding of the specific needs of NeuroMotor Pen implementation in both primary care and neurology clinics. She works closely with clinicians and provides valuable feedback that allows constant improvement of the user interface.
Alex Dimelow
Michael Warner
Possessing a first-class honours degree in Biomedical Sciences from Newcastle University, Alex’s strong interest in neurology led him to complete a research project investigating biomarkers common to complex neuroinflammatory disorders. Professionally, Alex’s desire to be at the forefront of innovative science began at the biotechnology startup Biosignatures Ltd, in which he contributed to the development of novel biomarkers for use in cancer diagnostics. He is now motivated to build on prior experiences to develop his personal expertise and assist Manus with bringing AI-driven diagnostic devices to market at a global scale.
Michael achieved a First-class honours degree in Electrical and Electronic Engineering from Northumbria University. Possessing an understanding in multiple programming languages, IDE's, CAD and CAM softwares and being passionate about coding microcontrollers and problem solving, he develops and implements a robotic test set up.
Investors
Make a difference today
Our disruptive technology has the potential to be used across many applications such as screening and triage, diagnosis, drug treatment optimisation, drug development, rehabilitation and research to improve our understanding of neuromotor impairments. We are keen to continue collaborating with interested researchers, clinicians and practitioners on our research in different areas, as well as businesses for further development and rolling out the existing and new products worldwide.
Collaborators
